metoprolol has been researched along with Angiogenesis, Pathologic in 4 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metoprolol treatment for 2 weeks improved LV systolic function." | 5.35 | Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. ( Kerkelä, R; Kubin, AM; Leskinen, H; Pieviläinen, O; Ruskoaho, H; Serpi, R; Soini, Y; Tenhunen, O; Tolonen, AM; Vaskivuo, T, 2009) |
| "VEGF promoter polymorphisms +405 and -460 were examined in 596 CHF patients enrolled in the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF) study and in 187 healthy controls." | 5.11 | The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. ( De Boer, RA; Hall, AS; van der Meer, P; van der Steege, G; van Veldhuisen, DJ; Voors, AA; White, HL, 2005) |
| "HIF-1 activity in tumors depends on availability of the HIF-1α subunit, the levels of which increase under hypoxic conditions and through activation of oncogenes and/or inactivation of tumor suppressor genes." | 2.48 | Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. ( Choi, HK; Lee, K; Xia, Y, 2012) |
| "Metoprolol treatment for 2 weeks improved LV systolic function." | 1.35 | Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. ( Kerkelä, R; Kubin, AM; Leskinen, H; Pieviläinen, O; Ruskoaho, H; Serpi, R; Soini, Y; Tenhunen, O; Tolonen, AM; Vaskivuo, T, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, Y | 1 |
| Choi, HK | 1 |
| Lee, K | 1 |
| Wrobel, LJ | 1 |
| Le Gal, FA | 1 |
| Serpi, R | 1 |
| Tolonen, AM | 1 |
| Tenhunen, O | 1 |
| Pieviläinen, O | 1 |
| Kubin, AM | 1 |
| Vaskivuo, T | 1 |
| Soini, Y | 1 |
| Kerkelä, R | 1 |
| Leskinen, H | 1 |
| Ruskoaho, H | 1 |
| van der Meer, P | 1 |
| De Boer, RA | 1 |
| White, HL | 1 |
| van der Steege, G | 1 |
| Hall, AS | 1 |
| Voors, AA | 1 |
| van Veldhuisen, DJ | 1 |
1 review available for metoprolol and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Hypo | 2012 |
1 trial available for metoprolol and Angiogenesis, Pathologic
| Article | Year |
|---|---|
The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy.
Topics: Adrenergic beta-Antagonists; Case-Control Studies; Cohort Studies; Cytosine; Female; Follow-Up Studi | 2005 |
2 other studies available for metoprolol and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Inhibition of human melanoma growth by a non-cardioselective β-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Humans; | 2015 |
Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction.
Topics: Animals; Antihypertensive Agents; Apoptosis; Cell Count; Cell Proliferation; Heart Ventricles; Inter | 2009 |